{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:35:24Z","timestamp":1793831724374,"version":"4.6.1"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40620-017-0392-z","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T11:44:48Z","timestamp":1491392688000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":564,"title":["Cisplatin nephrotoxicity: a review of the literature"],"prefix":"10.1093","volume":"31","author":[{"given":"Sandhya","family":"Manohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"392_CR1","volume-title":"Comprehensive Cancer Center., Bristol Laboratories.: Cisplatin, current status and new developments","author":"AW Prestayko","year":"1980","unstructured":"Prestayko AW, Crooke ST, Carter SK, University of Alabama in Birmingham (1980) Comprehensive Cancer Center., Bristol Laboratories.: Cisplatin, current status and new developments. Academic Press, New York"},{"issue":"8","key":"392_CR2","first-page":"CD009776","volume":"2014","author":"J Liira","year":"2014","unstructured":"Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK, Ruotsalainen JH (2014) Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev 2014(8):CD009776","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"392_CR3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"AM Florea","year":"2011","unstructured":"Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3(1):1351\u20131371","journal-title":"Cancers (Basel)"},{"issue":"9","key":"392_CR4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994\u20131007","journal-title":"Kidney Int"},{"issue":"1","key":"392_CR5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.300.1.142","volume":"300","author":"DM Townsend","year":"2002","unstructured":"Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300(1):142\u2013148","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"392_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000042803.28024.92","volume":"14","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14(1):1\u201310","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"392_CR7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/030089169007600617","volume":"76","author":"L Cozzaglio","year":"1990","unstructured":"Cozzaglio L, Doci R, Colella G, Zunino F, Casciarri G, Gennari L (1990) A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 76(6):590\u2013594","journal-title":"Tumori"},{"issue":"1\u20132","key":"392_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0009-2797(89)90065-3","volume":"70","author":"F Zunino","year":"1989","unstructured":"Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70(1\u20132):89\u2013101","journal-title":"Chem Biol Interact"},{"issue":"1","key":"392_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/j.1875-9114.1996.tb02913.x","volume":"16","author":"M Gosland","year":"1996","unstructured":"Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16(1):16\u201339","journal-title":"Pharmacotherapy"},{"issue":"7","key":"392_CR10","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","volume":"89","author":"AK Godwin","year":"1992","unstructured":"Godwin AK, Meister A, O\u2019Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070\u20133074","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"392_CR11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/carcin\/20.4.553","volume":"20","author":"MH Hanigan","year":"1999","unstructured":"Hanigan MH, Gallagher BC, Townsend DM, Gabarra V (1999) Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20(4):553\u2013559","journal-title":"Carcinogenesis"},{"issue":"7","key":"392_CR12","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","volume":"14","author":"G Kemp","year":"1996","unstructured":"Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14(7):2101\u20132112","journal-title":"J Clin Oncol"},{"issue":"5","key":"392_CR13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08880010590964381","volume":"22","author":"J Sastry","year":"2005","unstructured":"Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22(5):441\u2013445","journal-title":"Pediatr Hematol Oncol"},{"issue":"9","key":"392_CR14","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/00005537-200409000-00030","volume":"114","author":"A Ekborn","year":"2004","unstructured":"Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G (2004) High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 114(9):1660\u20131667","journal-title":"Laryngoscope"},{"issue":"2","key":"392_CR15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/taap.1996.0233","volume":"140","author":"M Esposito","year":"1996","unstructured":"Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F, Gogioso L (1996) Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol 140(2):370\u2013377","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"392_CR16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0022-3565(24)39304-8","volume":"293","author":"M Viale","year":"2000","unstructured":"Viale M, Vannozzi MO, Pastrone I, Mariggio MA, Zicca A, Cadoni A, Cafaggi S, Tolino G, Lunardi G, Civalleri D et al (2000) Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Ther 293(3):829\u2013836","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"392_CR17","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490\u20132518","journal-title":"Toxins (Basel)"},{"issue":"4","key":"392_CR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307\u2013320","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"392_CR19","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","volume":"99","author":"ER Jamieson","year":"1999","unstructured":"Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467\u20132498","journal-title":"Chem Rev"},{"issue":"1","key":"392_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10863-006-9059-5","volume":"39","author":"KJ Cullen","year":"2007","unstructured":"Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39(1):43\u201350","journal-title":"J Bioenerg Biomembr"},{"issue":"11","key":"392_CR21","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1074\/jbc.M210284200","volume":"278","author":"A Mandic","year":"2003","unstructured":"Mandic A, Hansson J, Linder S, Shoshan MC (2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278(11):9100\u20139106","journal-title":"J Biol Chem"},{"issue":"5","key":"392_CR22","first-page":"997","volume":"16","author":"M Hirama","year":"2006","unstructured":"Hirama M, Isonishi S, Yasuda M, Ishikawa H (2006) Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep 16(5):997\u20131002","journal-title":"Oncol Rep"},{"issue":"2","key":"392_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nephro.2004.12.001","volume":"1","author":"C Isnard-Bagnis","year":"2005","unstructured":"Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H, Tostivint I, Deray G (2005) [Anticancer drug-induced nephrotoxicity]. Nephrol Ther 1(2):101\u2013114","journal-title":"Nephrol Ther"},{"issue":"4","key":"392_CR24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1523-1755.2002.kid553.x","volume":"62","author":"D Portilla","year":"2002","unstructured":"Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J, Price P, Li S (2002) Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 62(4):1208\u20131218","journal-title":"Kidney Int"},{"key":"392_CR25","doi-asserted-by":"crossref","unstructured":"Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D (2004) PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286(3):F572-580.","DOI":"10.1152\/ajprenal.00190.2003"},{"issue":"6","key":"392_CR26","doi-asserted-by":"crossref","first-page":"C1466","DOI":"10.1152\/ajpcell.00265.2005","volume":"289","author":"W Qian","year":"2005","unstructured":"Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M (2005) Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 289(6):C1466\u2013C1475","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"392_CR27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ki.2008.214","volume":"74","author":"S Periyasamy-Thandavan","year":"2008","unstructured":"Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z (2008) Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74(5):631\u2013640","journal-title":"Kidney Int"},{"issue":"3","key":"392_CR28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ijc.23086","volume":"122","author":"M Fraser","year":"2008","unstructured":"Fraser M, Bai T, Tsang BK (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122(3):534\u2013546","journal-title":"Int J Cancer"},{"issue":"3","key":"392_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.etp.2008.09.003","volume":"61","author":"YI Chirino","year":"2009","unstructured":"Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223\u2013242","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"392_CR30","doi-asserted-by":"crossref","first-page":"F166","DOI":"10.1152\/ajprenal.00401.2004","volume":"289","author":"G Ramesh","year":"2005","unstructured":"Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289(1):F166\u2013174","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"392_CR31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.bcp.2007.01.010","volume":"73","author":"M Jiang","year":"2007","unstructured":"Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z (2007) Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73(9):1499\u20131510","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"392_CR32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2004.02.029","volume":"40","author":"NI Weijl","year":"2004","unstructured":"Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40(11):1713\u20131723","journal-title":"Eur J Cancer"},{"issue":"1","key":"392_CR33","doi-asserted-by":"crossref","first-page":"F35","DOI":"10.1152\/ajprenal.00096.2015","volume":"309","author":"MH Solanki","year":"2015","unstructured":"Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, Kohn N, Metz CN: Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am J Physiol Renal Physiol 2015, 309(1):F35\u201347","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"392_CR34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrneph.2010.16","volume":"6","author":"A Gluba","year":"2010","unstructured":"Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J (2010) The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 6(4):224\u2013235","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"392_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2215","volume":"8","author":"H Kono","year":"2008","unstructured":"Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8(4):279\u2013289","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"392_CR36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.2007090982","volume":"19","author":"B Zhang","year":"2008","unstructured":"Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB (2008) TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19(5):923\u2013932","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"392_CR37","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.4049\/jimmunol.1000383","volume":"185","author":"RK Tadagavadi","year":"2010","unstructured":"Tadagavadi RK, Reeves WB (2010) Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. J Immunol 185(8):4904\u20134911","journal-title":"J Immunol"},{"issue":"2","key":"392_CR38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1523-1755.2004.00413.x","volume":"65","author":"G Ramesh","year":"2004","unstructured":"Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 65(2):490\u2013499","journal-title":"Kidney Int"},{"issue":"10","key":"392_CR39","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/ndt\/gfp242","volume":"24","author":"KP Kang","year":"2009","unstructured":"Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W (2009) Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24(10):3012\u20133020","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"392_CR40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","volume":"110","author":"G Ramesh","year":"2002","unstructured":"Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Investig 110(6):835\u2013842","journal-title":"J Clin Investig"},{"issue":"22","key":"392_CR41","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","volume":"99","author":"S Ishida","year":"2002","unstructured":"Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99(22):14298\u201314302","journal-title":"Proc Natl Acad Sci USA"},{"key":"392_CR42","doi-asserted-by":"crossref","unstructured":"Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296(3):F505\u2013511","DOI":"10.1152\/ajprenal.90545.2008"},{"key":"392_CR43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","volume":"48","author":"MD Hall","year":"2008","unstructured":"Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495\u2013535","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"392_CR44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccr.2010.04.011","volume":"17","author":"S Ishida","year":"2010","unstructured":"Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17(6):574\u2013583","journal-title":"Cancer Cell"},{"issue":"8","key":"392_CR45","first-page":"3632","volume":"44","author":"C Jacobs","year":"1984","unstructured":"Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW (1984) Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 44(8):3632\u20133635","journal-title":"Cancer Res"},{"issue":"5","key":"392_CR46","first-page":"388","volume":"14","author":"J Klein","year":"1991","unstructured":"Klein J, Bentur Y, Cheung D, Moselhy G, Koren G (1991) Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Investig Med 14(5):388\u2013394","journal-title":"Clin Investig Med"},{"issue":"6","key":"392_CR47","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/1097-0142(19910315)67:6<1518::AID-CNCR2820670610>3.0.CO;2-3","volume":"67","author":"C Jacobs","year":"1991","unstructured":"Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67(6):1518\u20131524","journal-title":"Cancer"},{"key":"392_CR48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.physiol.60.1.243","volume":"60","author":"H Koepsell","year":"1998","unstructured":"Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243\u2013266","journal-title":"Annu Rev Physiol"},{"key":"392_CR49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10254-003-0017-x","volume":"150","author":"H Koepsell","year":"2003","unstructured":"Koepsell H, Schmitt BM, Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36\u201390","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"4","key":"392_CR50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396\u2013402","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"392_CR51","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176(3):1169\u20131180","journal-title":"Am J Pathol"},{"issue":"6","key":"392_CR52","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","volume":"167","author":"G Ciarimboli","year":"2005","unstructured":"Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167(6):1477\u20131484","journal-title":"Am J Pathol"},{"issue":"5","key":"392_CR53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bcp.2010.11.016","volume":"81","author":"A Yonezawa","year":"2011","unstructured":"Yonezawa A, Inui K (2011) Organic cation transporter OCT\/SLC22A and H(+)\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81(5):563\u2013568","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"392_CR54","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.ASN.0000019413.78751.46","volume":"13","author":"Y Urakami","year":"2002","unstructured":"Urakami Y, Akazawa M, Saito H, Okuda M, Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13(7):1703\u20131710","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"392_CR55","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/1097-0142(19871201)60:11<2823::AID-CNCR2820601138>3.0.CO;2-C","volume":"60","author":"DT Sleijfer","year":"1987","unstructured":"Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60(11):2823\u20132828","journal-title":"Cancer"},{"issue":"7","key":"392_CR56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0024-3205(83)90299-0","volume":"32","author":"RS Goldstein","year":"1983","unstructured":"Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32(7):685\u2013690","journal-title":"Life Sci"},{"issue":"6","key":"392_CR57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","volume":"83","author":"JT Hartmann","year":"1999","unstructured":"Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83(6):866\u2013869","journal-title":"Int J Cancer"},{"issue":"2","key":"392_CR58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","volume":"65","author":"NE Madias","year":"1978","unstructured":"Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307\u2013314","journal-title":"Am J Med"},{"key":"392_CR59","volume-title":"Maxwell & Kleeman\u2019s clinical disorders of fluid and electrolyte metabolism","author":"MH Maxwell","year":"1994","unstructured":"Maxwell MH, Kleeman CR, Narins RG (1994) Maxwell & Kleeman\u2019s clinical disorders of fluid and electrolyte metabolism, 5th\u00a0edn. McGraw-Hill, Health Professions Division, New York","edition":"5"},{"issue":"6","key":"392_CR60","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-90-6-929","volume":"90","author":"RL Schilsky","year":"1979","unstructured":"Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90(6):929\u2013931","journal-title":"Ann Intern Med"},{"issue":"1","key":"392_CR61","first-page":"40","volume":"117","author":"RA Sutton","year":"1991","unstructured":"Sutton RA, Walker VR, Halabe A, Swenerton K, Coppin CM (1991) Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 117(1):40\u201343","journal-title":"J Lab Clin Med"},{"issue":"3\u20134","key":"392_CR62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0300-483X(82)90009-9","volume":"24","author":"RS Goldstein","year":"1982","unstructured":"Goldstein RS, Mayor GH, Rosenbaum RW, Hook JB, Santiago JV, Bond JT (1982) Glucose intolerance following cis-platinum treatment in rats. Toxicology 24(3\u20134):273\u2013280","journal-title":"Toxicology"},{"issue":"1","key":"392_CR63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/taap.1995.1003","volume":"130","author":"YK Kim","year":"1995","unstructured":"Kim YK, Byun HS, Kim YH, Woo JS, Lee SH (1995) Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 130(1):19\u201326","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"392_CR64","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.tiv.2006.04.002","volume":"20","author":"GW Wangila","year":"2006","unstructured":"Wangila GW, Nagothu KK, Steward R, 3rd, Bhatt R, Iyere PA, Willingham WM, Sorenson JR, Shah SV, Portilla D (2006) Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutylsalicylate)4(ethanol)4]. Toxicol In Vitro 20(8):1300\u20131312","journal-title":"Toxicol In Vitro"},{"issue":"779","key":"392_CR65","first-page":"375","volume":"98","author":"CP Swainson","year":"1985","unstructured":"Swainson CP, Colls BM, Fitzharris BM (1985) Cis-platinum and distal renal tubule toxicity. NZ Med J 98(779):375\u2013378","journal-title":"NZ Med J"},{"issue":"2","key":"392_CR66","first-page":"F175","volume":"241","author":"R Safirstein","year":"1981","unstructured":"Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C (1981) Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241(2):F175\u2013185","journal-title":"Am J Physiol"},{"issue":"1","key":"392_CR67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000167938","volume":"9","author":"AC Seguro","year":"1989","unstructured":"Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A (1989) Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol 9(1):59\u201365","journal-title":"Am J Nephrol"},{"issue":"1","key":"392_CR68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","volume":"101","author":"AM Jackson","year":"1984","unstructured":"Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101(1):41\u201344","journal-title":"Ann Intern Med"},{"issue":"3","key":"392_CR69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0272-6386(86)80020-8","volume":"8","author":"M Lam","year":"1986","unstructured":"Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8(3):164\u2013169","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"392_CR70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-005-1010-7","volume":"56","author":"H Lajer","year":"2005","unstructured":"Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, Ostergaard LF, Christensen S, Daugaard G, Jonassen TE (2005) Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56(5):535\u2013542","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"392_CR71","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.ki.5000433","volume":"69","author":"D Portilla","year":"2006","unstructured":"Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, Safirstein RL, Beger RD (2006) Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69(12):2194\u20132204","journal-title":"Kidney Int"},{"issue":"5","key":"392_CR72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1681\/ASN.V125875","volume":"12","author":"SW Kim","year":"2001","unstructured":"Kim SW, Lee JU, Nah MY, Kang DG, Ahn KY, Lee HS, Choi KC (2001) Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 12(5):875\u2013882","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"392_CR73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115\u2013124","journal-title":"Am J Med Sci"},{"issue":"3","key":"392_CR74","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0041-008X(83)90266-1","volume":"69","author":"RS Goldstein","year":"1983","unstructured":"Goldstein RS, Mayor GH, Gingerich RL, Hook JB, Rosenbaum RW, Bond JT (1983) The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 69(3):432\u2013441","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"392_CR75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002800050661","volume":"40","author":"DJ Stewart","year":"1997","unstructured":"Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40(4):293\u2013308","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"392_CR76","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1987.5.2.304","volume":"5","author":"PA Reece","year":"1987","unstructured":"Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304\u2013309","journal-title":"J Clin Oncol"},{"issue":"10","key":"392_CR77","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/bjc.1998.276","volume":"77","author":"R Skinner","year":"1998","unstructured":"Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77(10):1677\u20131682","journal-title":"Br J Cancer"},{"issue":"11","key":"392_CR78","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/17.11.1931","volume":"17","author":"K Caglar","year":"2002","unstructured":"Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu S, Yavuz I, Yenicesu M, Ozet A et al (2002) Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 17(11):1931\u20131935","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"392_CR79","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/019262338601400215","volume":"14","author":"H Tanaka","year":"1986","unstructured":"Tanaka H, Ishikawa E, Teshima S, Shimizu E (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14(2):247\u2013257","journal-title":"Toxicol Pathol"},{"issue":"5","key":"392_CR80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/01926230490508821","volume":"32","author":"AE Vickers","year":"2004","unstructured":"Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32(5):577\u2013590","journal-title":"Toxicol Pathol"},{"issue":"2","key":"392_CR81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","volume":"50","author":"TL Cornelison","year":"1993","unstructured":"Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50(2):147\u2013158","journal-title":"Gynecol Oncol"},{"issue":"6","key":"392_CR82","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.09980912","volume":"8","author":"IA Dekkers","year":"2013","unstructured":"Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, van den Heuvel-Eibrink MM (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol CJASN 8(6):922\u2013929","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"392_CR83","doi-asserted-by":"crossref","unstructured":"Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW: Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2013(10):CD008944","DOI":"10.1002\/14651858.CD008944.pub2"},{"issue":"2","key":"392_CR84","doi-asserted-by":"crossref","first-page":"F469","DOI":"10.1152\/ajprenal.00038.2005","volume":"289","author":"S Li","year":"2005","unstructured":"Li S, Gokden N, Okusa MD, Bhatt R, Portilla D: Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005, 289(2):F469\u2013480","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"392_CR85","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1046\/j.1523-1755.2001.00043.x","volume":"60","author":"J Deng","year":"2001","unstructured":"Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S et al (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60(6):2118\u20132128","journal-title":"Kidney Int"},{"issue":"11","key":"392_CR86","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10715762.2016.1228923","volume":"50","author":"N Rani","year":"2016","unstructured":"Rani N, Bharti S, Tomar A, Dinda AK, Arya DS, Bhatia J (2016) Inhibition of PARP activation by enalapril is crucial for its renoprotective effect in cisplatin-induced nephrotoxicity in rats. Free Radic Res 50(11):1226\u20131236","journal-title":"Free Radic Res"},{"issue":"2","key":"392_CR87","doi-asserted-by":"crossref","first-page":"F378","DOI":"10.1152\/ajprenal.00192.2003","volume":"286","author":"PM Price","year":"2004","unstructured":"Price PM, Safirstein RL, Megyesi J: Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 2004, 286(2):F378\u2013384","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-017-0392-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0392-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0392-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:57:16Z","timestamp":1777564636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/31\/1\/15\/8371342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s40620-017-0392-z","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]}}}